Choline C-11 Injection Finds Prostate Cancer

Share this:

Each year about 90,000 men seek treatment for recurrent prostate cancer, and evaluating them for recurrence is a major challenge. Physicians have to wait until a patient’s prostate-specific antigen (PSA) levels rise to a certain level to identify sites of the recurrence.

Now Mayo Clinic has received U.S. Food and Drug Administration approval to produce and administer Choline C-11 Injection, an imaging agent used during a positron emission tomography (PET) scan to help detect sites of recurrent prostate cancer.

Click here for news release

Animation, b-roll and sound bites with Eugene Kwon, M.D. and Val Lowe, M.D. are available in the downloads.

Expert titles for broadcast cg:
Dr. Eugene Kwon, Mayo Clinic Urologist
Dr. Val Lowe, Mayo Clinic Radiologist

Related Articles

Neurosciences

Mayo Clinic Minute: Treatment and research of glioblastoma

Cancer

Esophageal cancer — know the signs and reduce your risk

Cancer

Teamwork and a new nickname inspire patient through pancreatic cancer treatment